Last reviewed · How we verify

Lopinavir-Monotherapy

Cantonal Hospital of St. Gallen · FDA-approved active Small molecule ✓ Verified May 2026 Quality 2/100

Lopinavir-Monotherapy is a Small molecule drug developed by Cantonal Hospital of St. Gallen. It is currently FDA-approved. Also known as: Kaletra.

Lopinavir monotherapy is used to treat HIV infection. It is compared to triple therapy with a boosted protease inhibitor in terms of quality of life for HIV-positive patients.

At a glance

Generic nameLopinavir-Monotherapy
Also known asKaletra
SponsorCantonal Hospital of St. Gallen
ModalitySmall molecule
PhaseFDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Lopinavir-Monotherapy

What is Lopinavir-Monotherapy?

Lopinavir-Monotherapy is a Small molecule drug developed by Cantonal Hospital of St. Gallen.

Who makes Lopinavir-Monotherapy?

Lopinavir-Monotherapy is developed and marketed by Cantonal Hospital of St. Gallen (see full Cantonal Hospital of St. Gallen pipeline at /company/cantonal-hospital-of-st-gallen).

Is Lopinavir-Monotherapy also known as anything else?

Lopinavir-Monotherapy is also known as Kaletra.

What development phase is Lopinavir-Monotherapy in?

Lopinavir-Monotherapy is FDA-approved (marketed).

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing